Aster DM Healthcare | Business Upturn

Aster DM Healthcare shares surge over 10% after strong Q4 Results; Net profit jumps 80.4% YoY

Aman Shukla — Mon, 04 May 2026 04:18:21 +0000

Shares of Aster DM Healthcare rallied more than 10% in early trade on Monday after the company reported a strong set of earnings for the fourth quarter of FY26, driven by robust revenue growth and significant expansion in profitability.

The healthcare major posted an 18.2% year-on-year (YoY) rise in consolidated revenue, which came in at Rs. 1,182 crore compared to Rs. 1,000 crore in the same quarter last year. The steady growth in topline reflects improved patient volumes and operational performance across its hospital and healthcare network.

Operating performance also showed notable improvement during the quarter. EBITDA rose 21.1% YoY to Rs. 233 crore from Rs. 192 crore, while EBITDA margin expanded slightly to 19.7% from 19.2%. The margin expansion highlights better cost efficiencies and stronger contribution from high-margin segments.

The standout figure in the earnings report was the sharp jump in net profit. The company reported a net profit of Rs. 163 crore in Q4FY26, marking a massive 80.4% increase compared to Rs. 90.5 crore in the corresponding quarter last year.

Aster DM Healthcare announces Rs 3 interim dividend per share for FY 2025-26

Arunika Jain — Fri, 27 Mar 2026 13:13:48 +0000

Aster DM Healthcare has declared an interim dividend of ₹3 per equity share for the financial year 2025-26. The announcement was made during the Board of Directors meeting held on March 26, 2026. The record date for determining the entitlement of shareholders to receive the interim dividend has been set for April 3, 2026.

In accordance with the provisions of the Income-tax Act, 2025, any dividend paid or distributed by a company is taxable in the hands of the shareholders. Consequently, Aster DM Healthcare will deduct tax at source when making the interim dividend payment.

For resident shareholders, the tax deduction at source (TDS) will be applied at a rate of 10% for those with a valid Permanent Account Number (PAN). However, if the PAN is invalid or not linked with an Aadhar number, the TDS rate will be 20%. Exemptions from TDS are available for certain categories, such as insurance companies, mutual funds, and alternative investment funds, upon submission of the requisite documents.

Non-resident shareholders will be subject to a withholding tax rate of 20% or as per the applicable Double Tax Avoidance Agreement (DTAA) between India and their country of residence. To avail of the DTAA benefits, non-resident shareholders must provide a Tax Residency Certificate, a self-declaration in Form 41, and other relevant documents.

The detailed communication regarding the TDS provisions and the necessary annexures to be submitted has been circulated to shareholders whose email addresses are registered with the company or depositories. The information is also available on the company’s website.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Aster DM Healthcare secures 96.68% shareholder approval for merger with QCIL

Business Desk — Wed, 11 Mar 2026 16:51:21 +0000

Aster DM Healthcare Limited has received an overwhelming 96.68% voting approval from its shareholders for the proposed merger with Quality Care India Limited (QCIL). The merger is set to create one of India’s top three hospital chains.

The approval from shareholders, including a significant majority of minority shareholders and creditors, marks a major milestone for the Scheme of Amalgamation. The merger, which had already received approvals from the Competition Commission of India (CCI) and stock exchanges, is expected to be completed in the next quarter, pending final regulatory and statutory approvals from the National Company Law Tribunal (NCLT).

Dr. Azad Moopen, Founder Chairman of Aster DM Healthcare, expressed confidence in the strategic rationale of the merger, highlighting the potential to build a future-ready healthcare platform. The combined entity, Aster DM Quality Care Ltd, will operate 39 hospitals with over 10,625 beds across 9 states and 28 cities, supported by more than 36,307 employees and clinicians.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Aster DM Healthcare secures 100% approval for amalgamation scheme from creditors

Business Desk — Wed, 11 Mar 2026 12:12:47 +0000

Aster DM Healthcare’s unsecured trade creditors have overwhelmingly approved the Scheme of Amalgamation with Quality Care India Limited. The resolution received 100% votes in favour from the creditors who participated in the voting process.

The meeting, held on 10 March 2026 via video conferencing, was convened following the directions of the National Company Law Tribunal, Hyderabad Bench. The scheme required approval from a majority representing three-fourths in value of the unsecured trade creditors. Out of 1,116 creditors, 51 attended the meeting, and all votes cast were in favour of the scheme.

The voting process was conducted through remote e-voting from 6 March to 9 March 2026, and during the meeting itself. The scrutiniser, Mr. Mohit Kumar Goyal, confirmed the voting results, which are also available on the company’s website.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Aster DM Healthcare appoints Dr. Azad Moopen as Executive Director

Business Desk — Tue, 10 Mar 2026 13:36:08 +0000

Aster DM Healthcare has announced the appointment of Dr. Azad Moopen as Executive Director, effective from 15 April 2026 to 28 May 2028. This decision was made during the company’s board meeting held on 10 March 2026, following recommendations from the Nomination and Remuneration Committee and the approval of the Audit Committee.

Dr. Moopen, who is currently the Chairman of Aster DM Healthcare, will continue in this role alongside his new responsibilities. He has been a pivotal figure in the company since its inception, transforming it from a single-doctor clinic in Dubai in 1987 into a leading global healthcare organisation. Dr. Moopen holds a Gold Medal in MBBS and a Post-Graduate degree in General Medicine from Calicut Government Medical College, Kerala, and a Diploma in Chest Diseases from Delhi University.

His appointment is subject to shareholder approval via postal ballot. Dr. Moopen’s leadership is recognised for its contribution to the company’s strategic vision, operational framework, and market positioning. He is also the father of Ms. Alisha Moopen, Deputy Managing Director, and Dr. Zeba Azad Moopen, Non-Executive Director.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Aster DM Healthcare CEO of Digital Health Dr. Harsha Rajaram resigns

Aman Shukla — Tue, 30 Sep 2025 06:27:14 +0000

Aster DM Healthcare has announced that Dr. Harsha Rajaram, CEO of Aster Digital Health and a senior management leader at the company, has resigned from his position, effective from the close of business hours on September 30, 2025. Dr. Rajaram cited personal commitments as the reason for his departure.

In his resignation, Dr. Rajaram expressed gratitude for his tenure at Aster DM Healthcare, highlighting the privilege of leading the digital transformation initiatives in India. He acknowledged the support of Dr. Azad Moopen and Ms. Alisha Moopen, as well as the contributions of leadership teams across India and the GCC, emphasizing that digital transformation is as much about cultural change as it is about technology.

“I am proud to leave behind a committed team and a strong digital foundation that can serve as a launchpad for Aster’s future in phygital healthcare. I remain committed to ensuring a smooth transition and supporting the organization during this period,” Dr. Rajaram stated in his resignation letter.

Aster DM Healthcare has confirmed that all necessary disclosures related to this management change have been filed in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company thanked Dr. Rajaram for his leadership and contributions to its digital initiatives.

Aster DM acquires additional 13% stake in DRCM for Rs 63 crore, enters lease agreement for 500-bed hospital in Bengaluru

Aman Shukla — Wed, 30 Jul 2025 05:59:38 +0000

Aster DM Healthcare has announced key strategic developments aimed at expanding its footprint in India. In a meeting held on July 30, 2025, the company’s Investment and Finance Committee approved two major decisions: increasing its stake in a key subsidiary and signing a lease for a new super-specialty hospital in Bengaluru.

The company will acquire an additional 13% equity in Dr. Ramesh Cardiac & Multispecialty Hospital Pvt Ltd (DRCM), increasing its total shareholding from 57.49% to 70.49%. This INR 63.01 crore cash deal comes as part of a put option exercised by DRCM’s promoters under the 2016 shareholders agreement. DRCM, based in Andhra Pradesh, reported a turnover of ₹258 crore in FY25.

In a parallel move, Aster has entered into a lease agreement with KEMWELL Private Limited for a composite property in Yeshwanthpur, Bengaluru. The company plans to set up a 500-bed super-specialty hospital on the site, with operations expected to begin in H2 FY28-29. This ₹580 crore investment will be funded through internal accruals and bank loans. The new hospital will serve the fast-growing northwest Bengaluru corridor, offering advanced tertiary care with excellent metro and rail connectivity.

These initiatives reflect Aster’s continued focus on expanding its healthcare network across India and strengthening its position in the high-growth southern market.

Aster DM Healthcare to set up new 430-bed hospital in Bengaluru’s Sarjapur area

Aditya Bhagchandani — Tue, 06 May 2025 17:31:43 +0000

Aster DM Healthcare has announced the signing of a lease agreement to establish a new multi-specialty hospital in Bengaluru. The facility will be located on Sarjapur Road, a rapidly developing locality in the city, and will add 430 beds to the company’s existing capacity.

According to the exchange filing dated May 6, 2025, the hospital will be developed in phases—300 beds by FY27 and the remaining 130 beds by FY29. The project will be executed on a built-to-suit leased property with a tenure of 30 years, secured with an interest-free refundable deposit of ₹58.65 crore.

The proposed hospital will be strategically located in one of Bengaluru’s emerging IT hubs, enabling Aster to cater to the growing demand for quality healthcare from the rising urban population. The company sees this investment as a significant step toward reinforcing its presence in South India, especially as Sarjapur evolves into a major commercial and residential zone.

The total investment in the project is estimated to be ₹480 crore, funded through internal accruals and bank loans. The planned facility will offer comprehensive cancer care alongside other specialty services.

As of December 31, 2024, Aster had a total bed capacity of 5,128 beds, with an occupancy rate of 67%. The expansion is expected to bolster Aster’s ability to serve a broader patient base while aligning with its long-term growth strategy.

Aster DM Healthcare shares surge 2% after HSBC raises target price to Rs 550

Aman Shukla — Fri, 29 Nov 2024 05:11:09 +0000

Aster DM Healthcare’s stock saw 2% increase after HSBC maintained a positive outlook for the company, raising the target price to ₹550.

HSBC has shown confidence in India’s hospital sector, forecasting significant growth with a focus on capacity expansion in 2025. Seven hospitals under coverage are expected to account for around 40% of the planned bed additions, signaling robust revenue growth.

Despite this optimism, HSBC warns that EBITDA margins may face some pressure due to increased capital expenditures associated with expansion. However, the overall revenue outlook remains strong, with the sector benefiting from rising healthcare demand.

Aster DM Healthcare shares opened at ₹502, with a daily high of ₹and a low of ₹490.10. The stock remains well within range of its 52-week high of ₹558 and low of ₹311.10, indicating healthy performance and investor confidence.

As of 10:41 am, Aster DM Healthcare shares were trading 2.41% higher at Rs 500.50 on the NSE.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Aster DM Healthcare to establish new women & children hospital in Hyderabad

News Desk — Sun, 22 Sep 2024 07:21:09 +0000

Aster DM Healthcare Limited, through its wholly-owned subsidiary, Sri Sainatha Multispecialty Hospitals Private Limited, has entered into a lease agreement with Aparna Constructions and Estates Private Limited on September 22, 2024. The agreement is aimed at establishing a new Aster Women and Children Hospital in Hyderabad.

The hospital will be developed in two phases, with a proposed capacity addition of 275 to 300 beds. The total investment required for the project is estimated to be ₹220 crore, which will be financed through bank loans and internal accruals. The hospital will cater to the growing healthcare needs of Hyderabad’s expanding population, with a focus on specialized maternal and pediatric care.

The lease agreement spans a period of 30 years, with a refundable security deposit of ₹9.70 crores. This strategic move comes in response to Hyderabad’s rising demand for comprehensive women’s and children’s healthcare services, positioning the new hospital to serve the city’s booming middle class and medical tourism market.

The hospital’s location in a catchment area populated by young migrants will enable it to address the increasing demand for specialized care, particularly with limited options available for high-end super-specialty services in the region.

Aster DM shares surge nearly 5% as company’s Q1FY25 net profit jumps to ₹5,152 crore

Aditya Bhagchandani — Thu, 01 Aug 2024 04:24:12 +0000

Aster DM Healthcare’s shares jumped nearly 5% on Wednesday following the company’s impressive financial results for the first quarter ending June 30, 2024.

Key Financial Highlights

Net Profit:
- Current Quarter: ₹5,152.2 crore
- Previous Year: ₹20 crore
Revenue from Operations:
- Current Quarter: ₹565.7 crore
- Previous Year: ₹457.2 crore
- Increase: 23.7%
EBITDA:
- Current Quarter: ₹101.3 crore
- Previous Year: ₹83 crore
- Increase: 22%
EBITDA Margin:
- Current Quarter: 17.95%
- Previous Year: 18.2%

Performance Details

Exceptional Gain: ₹372.7 crore
Average Revenue Per Occupied Bed (ARPOB): Exceeded ₹70,000
Occupancy at Whitefield Hospital, Bengaluru: 65%
Revenue Growth:
- Karnataka and Maharashtra Cluster: 38% year-on-year
- Aster Labs: 15% year-on-year

Strategic Developments

GCC Business Separation: Completed on April 3, 2024
Dividend Received: ₹5,569.96 crore from Affinity Holdings Private Ltd
Preference Shares Redemption: ₹1,828.52 crore, resulting in a gain of ₹372.7 crore

Financial Metric	Current Quarter	Previous Year	Change
Net Profit	₹5,152.2 crore	₹20 crore	+25,661%
Revenue from Operations	₹565.7 crore	₹457.2 crore	+23.7%
EBITDA	₹101.3 crore	₹83 crore	+22%
EBITDA Margin	17.95%	18.2%	-0.25 percentage points
Exceptional Gain	₹372.7 crore	N/A	N/A
ARPOB	> ₹70,000	N/A	N/A
Whitefield Hospital Occupancy	65%	N/A	N/A
Revenue Growth (Karnataka & Maharashtra)	38%	N/A	N/A
Revenue Growth (Aster Labs)	15%	N/A	N/A
Dividend Received from Affinity Holdings	₹5,569.96 crore	N/A	N/A
Preference Shares Redemption	₹1,828.52 crore	N/A	N/A
Shares Trading	₹362.30	N/A	+4.39%

Market Reaction

Shares Trading: 4.39% higher at ₹362.30 on NSE as of 9:50 AM

Aster DM Healthcare shares fall after Q4 net loss

Aditya Bhagchandani — Wed, 29 May 2024 05:25:20 +0000

Shares of Aster DM Healthcare dropped in early trade on May 29 after the hospital company reported a net loss for the January-March quarter of FY24. The stock, however, quickly recouped much of its losses.

Aster DM Healthcare posted a net loss of Rs 24 crore in Q4FY24, compared to a net profit of Rs 170.8 crore in the same period last year. The bottom line was impacted by higher tax expenses and contributions from discontinued operations.

Despite the net loss, the company saw revenue growth of 20.65%, reaching Rs 973.6 crore, up from Rs 806.9 crore in the previous fiscal year’s same quarter. The company’s operational performance improved as well, with Average Revenue Per Occupied Bed (ARPOB) showing positive trends. EBITDA margin expanded by 100 basis points, reaching 16.4% in Q4.

As of 10:50 am, the shares were trading 1.50% lower at ₹373.90 on the NSE.

Stocks To Watch: Aster DM Healthcare share price in focus on the back of special dividend

Markets Desk — Sun, 14 Apr 2024 11:28:21 +0000

Shares of Aster DM Healthcare will be in focus in tomorrow’s trade (Monday, April 15) as the company has announced a special dividend of Rs 118 per share for its shareholders. This decision comes after the company had initially indicated a range of Rs 110-120 per share, positioning the special dividend at the higher end of the spectrum.

The record date for this special dividend has been set for April 23rd, with the dividend expected to be disbursed within 30 days of the record date. Notably, the board has decided against declaring an interim dividend for the fiscal year 2023-24, with the possibility of a final dividend being considered at the Q4 board meeting for the same financial year.

The special dividend, stemming from the proceeds of the sale of the Gulf Cooperation Council (GCC) business and the redemption of redeemable preference shares issued by Affinity Holdings Pvt Ltd, a wholly-owned subsidiary of Aster DM Healthcare, marks a significant move by the company.

The sale of the GCC business, which brought in $907.8 million (Rs 7588 crore) for Aster DM Healthcare, has been a pivotal development for the company. This sale was part of a strategic move to separate the India and GCC businesses, aiming to unlock long-term value by operating as two distinct entities.